Mineralys Therapeutics Reports Q1 2026 Financial Results with $39.3M Net Loss

Mineralys Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $39.3 million, a decrease from the $42.2 million loss recorded in the same period of 2025. The company’s total operating expenses for the quarter were $45.3 million, slightly up from $44.4 million year-over-year. Research and development expenses decreased significantly to $24.4 million from $37.9 million, primarily due to the completion of pivotal clinical trials for its lead product candidate, lorundrostat. In contrast, general and administrative expenses surged to $21.0 million, up from $6.6 million, reflecting increased professional fees and personnel costs as the company prepares for potential product commercialization.

As of March 31, 2026, Mineralys held cash, cash equivalents, and investments totaling $646.1 million, a decrease from $661.8 million at the end of 2025. The company’s accumulated deficit increased to $496.5 million from $457.2 million over the same period. The decline in cash and cash equivalents was attributed to net cash used in operating activities of $39.5 million, which was lower than the $45.5 million used in the prior year, indicating improved cash management. The company also reported net cash provided by financing activities of $24.3 million, primarily from the sale of common stock under its At-the-Market (ATM) equity offering agreement.

Strategically, Mineralys has made significant progress with its product candidate, lorundrostat, which is being developed for the treatment of hypertension and related conditions. The company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in December 2025, which has been accepted with a target decision date of December 22, 2026. The company has completed six clinical trials for lorundrostat, demonstrating its efficacy and safety profile. Additionally, the company is conducting an open-label extension trial, Transform-HTN, to gather long-term safety and efficacy data.

Operationally, Mineralys has expanded its workforce to support its growing pre-commercial activities, with a notable increase in personnel-related expenses. The company’s employee headcount has risen as it builds out its capabilities in preparation for a potential product launch. The company has also engaged in strategic financing activities, raising approximately $20.2 million from the sale of common stock under its ATM agreement during the quarter. This funding is crucial as the company anticipates increased expenses related to regulatory activities, market access, and the establishment of commercial functions.

Looking ahead, Mineralys expects to continue incurring significant losses as it advances its clinical development and prepares for the potential launch of lorundrostat. The company plans to finance its operations through equity offerings, debt financings, and other capital sources, while also exploring strategic collaborations. The management believes that its current cash reserves will be sufficient to fund operations for at least the next twelve months, although future capital requirements will depend on various factors, including the timing and costs of clinical trials and regulatory approvals.